Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review
Acta Dermato-Venereologica · 27.05.2025 · 105 · adv43588
DOI: 10.2340/actadv.v105.43588 ↗Kurz gefasst
Fallbericht in der Zeitschrift Acta Dermato-Venereologica, online erschienen am 27.05.2025. Verfasst von Shihua Ling und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China; Shantou University Medical College, Shantou, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China; Shantou University Medical College, Shantou, China.
- Department of Dermatology, Peking University Shenzhen Hospital, Shenzhen, China. drdouxia@163.com.
Zitieren
APA
Ling, S., & Dou, X. (2025). Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review. Acta Dermato-Venereologica, 105, adv43588. https://doi.org/10.2340/actadv.v105.43588
Vancouver
Ling S, Dou X. Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review. Acta Dermato-Venereologica. 2025;105:adv43588. doi:10.2340/actadv.v105.43588
BibTeX
@article{Ling2025,
author = {Ling, Shihua and Dou, Xia},
title = {Real–world Experience with JAK Inhibitors and Dupilumab in Dystrophic Epidermolysis Bullosa: A Case Report and Literature Review},
journal = {Acta Dermato-Venereologica},
year = {2025},
volume = {105},
pages = {adv43588},
doi = {10.2340/actadv.v105.43588}
}
EUVIMED